Back to Journals » OncoTargets and Therapy » Volume 8

Downregulation of microRNA-132 by DNA hypermethylation is associated with cell invasion in colorectal cancer

Authors Qin J, Ke J, Xu J, Wang F, Zhou Y, Jiang Y, Wang Z

Received 1 July 2015

Accepted for publication 13 October 2015

Published 7 December 2015 Volume 2015:8 Pages 3639—3648

DOI https://doi.org/10.2147/OTT.S91560

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Ram Prasad

Peer reviewer comments 3

Editor who approved publication: Dr Faris Farassati


Jun Qin, Jing Ke, Junfei Xu, Feiran Wang, Youlang Zhou, Yasu Jiang, Zhiwei Wang

Department of General Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu Province, People’s Republic of China

Abstract: microRNAs (miRNAs) are small, noncoding RNAs that are involved in many biological processes, and aberrant regulation of miRNAs is always associated with cancer progression and development. Abnormal expression of miRNA-132 (miR-132) has been found in some types of cancer, but the effects and potential mechanisms of miR-132 in colorectal cancer (CRC) have not been explored to date. In this study, quantitative real-time polymerase chain reaction was used to investigate the level of miR-132 in CRC tissues and their paired adjacent normal tissues. Bioinformatics analysis indicated that the mechanism underlying the tumor suppressor role of miR-132 in CRC cells may play a role in tumor suppression by targeting paxillin. Furthermore, methylation-specific polymerase chain reaction was performed to evaluate the methylation status of the miR-132 regulatory region. A DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine, was used to activate the expression of miR-132 in CRC cells in vitro. Downregulation of miR-132 may occur as a result of hypermethylation and implies a poor prognosis in CRC; therefore, triggering miR-132 reexpression by using DNA methyltransferase inhibitors may be a potential molecular therapeutic target for CRC.

Keywords: microRNA-132, colorectal cancer, DNA methylation, invasion

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]